An Analysis of the Relationship Between the Genetic Polymorphisms of Interleukin 12 Receptor Subunit Beta 1 and Crohn's Disease in Chinese Patients

Sponsor
Second Affiliated Hospital of Wenzhou Medical University
Study ID
NCT07057856
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Accepted

Interventions

  • Ustekinumab (UST) — BIOLOGICAL
    The first sufficient dose of UST (6mg/kg) was administered intravenously at weeks 0

Study Details

From January 2018 to May 2025, diagnosed CD patients and gender- and age-matched normal controls were collected from Department of Gastroenterology, the Second Affiliated Hospital of Wenzhou Medical University. Our study aimed to explore the associations of interleukin 12 receptor subunit beta 1 (IL-12RB1) gene polymorphisms with the risk and clinicopathological characteristics of Crohn's disease (CD), and to analyze the effects of IL-12RB1 gene variations on the clinical response of ustekinumab (UST) treatment in CD patients at week 8.

Key Dates

Start date
Jan 1, 2018
Status verified
Jun 2025
Primary completion
May 31, 2025
Completion
May 31, 2025

Study Design

Enrollment
866 participants (actual)

Arms

  • Arm: CD patients
    Some CD patients received UST treatment and the first sufficient dose of UST (6mg/kg) was administered intravenously.
  • Arm: normal control
    no biological agents treatment

Primary Outcome Measure

Genotypes of IL-12RB1 [ Time Frame: Baseline ]

Related Studies